Bonus Policy
- Free Shipping for orders starting with $300.00!
- Free insurance (guaranteed reshipment if delivery failed) for orders starting with $300.00!
Short Description
Galvus (generic name: Vildagliptin) is a drug in a new class of oral diabetes medications called dipeptidyl peptidase-4 (DPP-4) inhibitors. It is used to treat type 2 or non-insulin dependent diabetes (NIDDM).
Galvus is used for people with type 2 diabetes whose blood sugar is not sufficiently controlled by other antidiabetic medicines. It can be added to treatment with metformin; a sulphonylurea, for example gliclazide; or another type of antidiabetic medicine known as a thiazolidinedione, for example pioglitazone or rosiglitazone.
Galvus works through a novel mechanism of action by targeting the dysfunction in the pancreatic islets that causes high blood sugar levels in people with type 2 diabetes. Islet dysfunction, along with insulin resistance, is a contributory factor in type 2 diabetes. In combination with the most widely prescribed type 2 diabetes medicines, Galvus delivers significant blood sugar reductions with a good tolerability profile in a broad range of patients. Galvus demonstrates strong efficacy in a broad patient population with over 14,000 patients treated in the clinical program to date.
Galvus and Eucreas, a single-pill combination of Galvus and metformin, are approved as oral treatments for type 2 diabetes patients in all 27 countries of the European Union as well as in Norway and Iceland. Galvus is currently available in 18 countries, namely Italy, the UK, Germany, Netherlands, Denmark, Norway, Greece, Malta, Poland, Ireland, Spain, Switzerland, Mexico, Brazil, Argentina, the Philippines, Singapore and India, and is approved in 51 countries.
